Pub. Date : 2006 Feb
PMID : 16443858
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | OBJECTIVE: To study the effect of the short-acting insulin secretagogue nateglinide in patients with maturity-onset diabetes of the young type 3 (MODY3), which is characterized by a defective insulin response to glucose and hypersensitivity to sulfonylureas. | Nateglinide | insulin | Homo sapiens |
| 2 | RESEARCH DESIGN AND METHODS: We compared the acute effect of nateglinide, glibenclamide, and placebo on prandial plasma glucose and serum insulin, C-peptide, and glucagon excursions in 15 patients with MODY3. | Nateglinide | insulin | Homo sapiens |
| 3 | RESULTS: Insulin peaked earlier after nateglinide than after glibenclamide or placebo (median [interquartile range] time 70 [50] vs. 110 [20] vs. 110 [30] min, P = 0.0002 and P = 0.0025, respectively). | Nateglinide | insulin | Homo sapiens |
| 4 | The improved prandial glucose control with nateglinide was achieved with a lower peak insulin concentration than after glibenclamide (47.0 [26.0] vs. 80.4 [71.7] mU/l; P = 0.023). | Nateglinide | insulin | Homo sapiens |
| 5 | CONCLUSIONS: A low dose of nateglinide prevents the acute postprandial rise in glucose more efficiently than glibenclamide and with less stimulation of peak insulin concentrations and less hypoglycemic symptoms. | Nateglinide | insulin | Homo sapiens |